These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20601445)

  • 41. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
    Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
    Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
    Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly JT; Stegelmann F; Bijou F; Lippert E; McMullin MF; Boiron JM; Döhner K; Vannucchi AM; Besses C; Campbell PJ; Green AR
    Blood; 2012 Sep; 120(13):2704-7. PubMed ID: 22898600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.
    Rinaldi CR; Rinaldi P; Alagia A; Gemei M; Esposito N; Formiggini F; Martinelli V; Senyuk V; Nucifora G; Pane F
    Blood; 2010 Dec; 116(26):6023-6. PubMed ID: 20861460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
    Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
    Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
    Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
    Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
    Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
    Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
    Lacout C; Pisani DF; Tulliez M; Gachelin FM; Vainchenker W; Villeval JL
    Blood; 2006 Sep; 108(5):1652-60. PubMed ID: 16670266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.
    Fung TK; Cheung AM; Kwong YL; Liang R; Leung AY
    Leuk Res; 2010 Oct; 34(10):1390-4. PubMed ID: 20170959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
    J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Expression of apoptosis related proteins in CD34 positive bone marrow cells of patients with polycythemia vera].
    Bai J; Shao ZH; Liu H; Shi J; Cao YR; Tu MF; Wu YH; Jia HR; Sun J; Cui ZZ; Qian LS; Yang CL
    Zhonghua Xue Ye Xue Za Zhi; 2004 Oct; 25(10):617-20. PubMed ID: 15634597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
    Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
    Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
    Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
    Lu M; Wang X; Li Y; Tripodi J; Mosoyan G; Mascarenhas J; Kremyanskaya M; Najfeld V; Hoffman R
    Blood; 2012 Oct; 120(15):3098-105. PubMed ID: 22872685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.
    Casolari DA; Nguyen T; Butcher CM; Iarossi DG; Hahn CN; Bray SC; Neufing P; Parker WT; Feng J; Maung KZY; Wee A; Vidovic L; Kok CH; Bardy PG; Branford S; Lewis ID; Lane SW; Scott HS; Ross DM; D'Andrea RJ
    Sci Rep; 2017 May; 7(1):2467. PubMed ID: 28550306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
    De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
    Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.